Shots:

• The P-III FINCH-3 study involves assessing of filgotinib (100/200 mg) + methotrexate (MTX) vs filgotinib (200mg)/MTX as monothx in 1252 patients in ratio (2:1:1:2) with moderate to severe active RA who are naive to MTX for @24 wks.
• P-III FINCH 3 results: ACR20 (80.2%- 81.2% vs 78.1%/71.4%); ACR50 (57%-61.5% vs 58.1%/ 45.7%); ACR70 (40.1%- 43.8% vs 40%/26%); DAS28(CRP) < 2.6 (42.5%- 54.1% vs 42.4%/29.1%); HAQ-DI change (-0.90- -0.94 vs -0.89/ -0.79); mTSS change (0.22- 0.20 vs -0.04/0.52); SAEs (2.4%- 4.1% vs 4.8%/2.9%)
• Filgotinib is an oral JAK1 inhibitor- evaluated in P-II EQUATOR study for psoriatic arthritis- P-III DIVERSITY study for Crohn’s disease. In Dec-2015 Gilead and Galapagos entered into a collaboration to develop and commercialize filgotinib

   Ref: Gilead | Image:Gilead